MetLife Investment Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.22M | Sell |
41,664
-1,834
| -4% | -$97.9K | 0.01% | 948 |
|
|
2025
Q1 | $1.76M | Buy |
43,498
+1,933
| +5% | +$78.2K | 0.01% | 1100 |
|
|
2024
Q4 | $1.16M | Buy |
41,565
+2,322
| +6% | +$64.6K | 0.01% | 1337 |
|
|
2024
Q3 | $1.13M | Hold |
39,243
| – | – | 0.01% | 1332 |
|
|
2024
Q2 | $921K | Buy |
39,243
+7,003
| +22% | +$164K | 0.01% | 1380 |
|
|
2024
Q1 | $814K | Buy |
32,240
+5,245
| +19% | +$132K | 0.01% | 1413 |
|
|
2023
Q4 | $630K | Hold |
26,995
| – | – | ﹤0.01% | 1556 |
|
|
2023
Q3 | $1.37M | Buy |
26,995
+3,311
| +14% | +$167K | 0.01% | 1073 |
|
|
2023
Q2 | $1.11M | Buy |
23,684
+5,405
| +30% | +$252K | 0.01% | 1215 |
|
|
2023
Q1 | $699K | Hold |
18,279
| – | – | 0.01% | 1437 |
|
|
2022
Q4 | $1M | Buy |
18,279
+2,699
| +17% | +$148K | 0.01% | 1212 |
|
|
2022
Q3 | $530K | Hold |
15,580
| – | – | ﹤0.01% | 1594 |
|
|
2022
Q2 | $147K | Hold |
15,580
| – | – | ﹤0.01% | 2509 |
|
|
2022
Q1 | $221K | Buy |
15,580
+5,750
| +58% | +$81.6K | ﹤0.01% | 2293 |
|
|
2021
Q4 | $208K | Hold |
9,830
| – | – | ﹤0.01% | 2028 |
|
|
2021
Q3 | $220K | Hold |
9,830
| – | – | ﹤0.01% | 2029 |
|
|
2021
Q2 | $244K | Buy |
9,830
+4,241
| +76% | +$105K | ﹤0.01% | 2031 |
|
|
2021
Q1 | $162K | Hold |
5,589
| – | – | ﹤0.01% | 2159 |
|
|
2020
Q4 | $144K | Hold |
5,589
| – | – | ﹤0.01% | 2142 |
|
|
2020
Q3 | $172K | Hold |
5,589
| – | – | ﹤0.01% | 1947 |
|
|
2020
Q2 | $139K | Buy |
+5,589
| New | +$139K | ﹤0.01% | 2088 |
|